US Regulation Of Fat Transfer Devices Shifts To FDA Biologics Center
The move is consistent with a 2007 guidance document, which said that devices that use human cells or tissue to create a therapeutic agent at the point of care should be regulated as biologics.
You may also be interested in...
The US agency issued a letter to providers in the wake of a study that found significantly higher complication rates in women implanted with Boston Scientific’s Watchman device.
Virtual and in-person events are planned for Washington, DC, and Minneapolis, MN, during the trade group gathering.
The US patent office has upheld all seven patents at issue, with the verdict on the final three having come on 22 September.